Menopausal Hot Flashes Market to Reach US$5.28 bn by 2023, Estrogen Leads Hormonal Products in Revenue and Prescription Volume

Jan 05, 2016, 09:30 ET from Transparency Market Research

ALBANY, New York, January 5, 2016 /PRNewswire/ --

Transparency Market Research has published a new market report titled, "Menopausal Hot Flashes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023." According to the report, the global menopausal hot flashes market was valued at US$3.77 bn in 2014 and is projected to expand at a CAGR of 3.7% from 2015 to 2023 to reach US$5.28 bn by 2023.

Browse the full Menopausal Hot Flashes Market: [By Product Type: Hormonal (Estrogen, Progesterone, and Combination), Non-Hormonal, (Brisdelle, and Other Anti-Depressants) Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 report at

Hot flashes are the most common vasomotor symptom of menopause complications. The usual symptoms include sudden sensation of intense warmth spreading over body lasting for several minutes leading to sweating, red flush, and palpitations. Hot flashes may occur during the day or at night (also known as night sweats). The intensity of hot flashes vary from woman to woman depending on several physiochemical factors. It may be mild, moderate and troublesome, or severe and debilitating. Hormone replacement therapy (HRT) has been considered as gold standard for the treatment of menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems. Other therapies include intake of vitamin E supplements and anti-depressants along with various complementary therapies. In the U.S. and other developed countries approximately 70% of menopausal women suffer from hot flashes that can last for several years. According to a publication by Harvard Medical School, on average, hot flashes can last for about 7 years to 11 years.

Get Sample Report Copy of Menopausal Hot Flashes Market:

The report explores the vast scope of menopausal hot flashes market and draws upon the market analysis through two broad perspectives: product, and geography. On the basis of product types, the market has been categorized into hormonal and non-hormonal products. Estrogen and progesterone are the two hormones used to reduce hot flashes. Furthermore, these hormones are also prescribed in combination in certain women with high risk cancer. Estrogen accounted for the largest share of the global menopausal hot flashes market in terms of revenue as well as prescription volume. Estrogen's position in hot flashes treatment market is unchallenged as none of the other available drug is as effective as estrogen.

Some of the recent studies show that non-estrogen drugs may have up to 70% of the effectiveness of estrogen therapy when treating hot flashes. Premarin was the largest selling estrogen product in 2014. The drug has recorded over billion sale in 2014. Combination drugs primarily include treatment with estrogen and progesterone prescribed to women with intact uterus and have moderate to severe symptoms of menopause. Amongst the combination product, Prempro, Duavee, and Activella were the major market share holders in 2014.

The aftermaths of the Women's Health Initiative study of HRT in menopausal women have encouraged many physicians to restrict the use of HRT to relieve hot flashes. Now a days, non-hormonal therapy is being considered as a treatment to avoid the increased risk of cancer in certain high risk populations. Non-hormonal therapy includes antidepressants and other prescription drugs that offer relief for some women. Brisdelle is the only antidepressant medication approved by the FDA for treating hot flashes.

The menopausal hot flashes market is highly fragmented due to the presence of large number of small and medium generic manufacturing companies across the world. Top ten manufacturers accounted for around 44.5% of the market in 2014. Key players operating in the market include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk Corporation, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

Browse Press Release of Menopausal Hot Flashes Market:

Key Segments of the Global Menopausal Hot Flashes Market:  

Global Menopausal Hot Flashes Market, by Product 

  • Hormonal Products
    • Estrogen
      • Premarin
      • Vivelle, Vivelle-Dot
    • Progesterone
      • Prometrium
    • Combination Product
      • Prempro
      • Duavee
    • Non-Hormonal Product
      • Brisdelle

Global Menopausal Hot Flashes Market, Pipeline Analysis 

  • Phase I and II Drugs
  • Phase III Drugs

Global Menopausal Hot Flashes Market, by Geography 

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • MENA

Other Reports by Transparency Market Research:  

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr. Sudip.S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

SOURCE Transparency Market Research